TSXV:NSP.H - Post by User
Comment by
brokeon Jan 22, 2021 11:18am
141 Views
Post# 32359354
RE:Vodcast Interview with CEO & Director Craig Goodwin Jan 19th
RE:Vodcast Interview with CEO & Director Craig Goodwin Jan 19thI am good with that. It was a thorough update.
Specially this part which provides clarity since last November 4th release.
(From Transcript)
SH: Are you able to update investors on the Plasm Joint Venture and the clinical trial for Cavaltinib as a Covid-19 treatment?
CG: I can. Our readers, our followers will know that we have been approved for a Phase II clinical trial.
This obviously when you start administering medicines to, you know, test subjects, the amount of documentation and preparation and protocols that carry it out are extensive, and they should be. So, from the point of getting permission to proceed with our Phase II clinical trial, an enormous amount of work has gone on behind the scenes. First of all, interviewing perspective companies that help you conduct these studies. So, I can see that that process is going extremely well. We look forward to providing an update in the very near future with this selection who will be carrying out these studies for us. Once the study begins, we expect that study to take approximately five weeks and then about a two-week break for it to analyze the data that we've collected. So, we have our approval. We are now down to the final decision making to a team that we will, or a company we will select , who will help us conduct the trials. And then after that, the five-to-seven week time period, until we have the results back that we can report through to our investors.